Restart Life Expands Intellectual Property Through Trademark Licensing Agreement
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) has secured exclusive licensing rights to four health-related trademarks under a 5-year agreement, renewable for another 5 years. The deal includes a nominal $1 licensing fee and royalty structure of 5% on gross sales up to $1,000,000, reducing to 2.5% for sales exceeding $1,000,000.
The agreement, made with a company controlled by one of Restart Life's directors, includes a previously revenue-generating health-care brand that operated on Amazon. Royalties can be paid in cash, company common shares, or a combination of both. Both parties have agreed to negotiate the purchase of the licensed trademarks at the end of the term.
The transaction is exempt from formal valuation requirements and minority shareholder approval requirements under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions.
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) ha ottenuto i diritti di licenza esclusivi su quattro marchi legati alla salute attraverso un accordo di 5 anni, rinnovabile per ulteriori 5 anni. L'accordo prevede una tassa di licenza nominale di $1 e una struttura di royalty del 5% sulle vendite lorde fino a $1.000.000, che si riduce al 2,5% per le vendite superiori a $1.000.000.
L'accordo, stipulato con una società controllata da uno dei direttori di Restart Life, include un marchio di assistenza sanitaria che generava precedentemente entrate e operava su Amazon. Le royalty possono essere pagate in contante, azioni ordinarie della società o una combinazione di entrambi. Entrambe le parti hanno concordato di negoziare l'acquisto dei marchi licenziati al termine del contratto.
La transazione è esente dai requisiti di valutazione formale e dai requisiti di approvazione degli azionisti di minoranza ai sensi dello Strumento Multilaterale 61-101 Protezione degli Azionisti di Minoranza nelle Transazioni Speciali.
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) ha obtenido los derechos de licencia exclusivos sobre cuatro marcas relacionadas con la salud a través de un acuerdo de 5 años, renovable por otros 5 años. El acuerdo incluye una tarifa de licencia nominal de $1 y una estructura de regalías del 5% sobre las ventas brutas hasta $1,000,000, que se reduce al 2.5% para las ventas que superan los $1,000,000.
El acuerdo, realizado con una empresa controlada por uno de los directores de Restart Life, incluye una marca de atención médica que anteriormente generaba ingresos y operaba en Amazon. Las regalías pueden pagarse en efectivo, acciones ordinarias de la empresa o una combinación de ambas. Ambas partes han acordado negociar la compra de las marcas licenciadas al final del plazo.
La transacción está exenta de requisitos de valoración formal y de aprobación de accionistas minoritarios bajo el Instrumento Multilateral 61-101 de Protección de Accionistas Minoritarios en Transacciones Especiales.
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD)는 5년 계약을 통해 건강 관련 상표 4개에 대한 독점 라이센스 권리를 확보했으며, 이 계약은 5년 더 연장 가능하다. 이 거래는 명목상 $1의 라이센스 수수료와 $1,000,000까지의 총 판매액에 대해 5%의 로열티 구조를 포함하고 있으며, $1,000,000를 초과하는 판매에 대해서는 2.5%로 줄어든다.
이 계약은 Restart Life의 이사 중 한 명이 지배하는 회사와 체결되었으며, 이전에 아마존에서 운영되던 수익을 창출한 의료 브랜드를 포함한다. 로열티는 현금, 회사의 보통주 또는 두 가지의 조합으로 지급될 수 있다. 양측은 계약 종료 시 라이센스 상표의 구매를 협상하기로 합의했다.
이 거래는 다자간 계약 61-101의 소수 주주 보호 조항에 따라 공식 평가 요구 사항과 소수 주주 승인 요구 사항에서 면제된다.
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) a obtenu des droits de licence exclusifs sur quatre marques liées à la santé dans le cadre d'un accord de 5 ans, renouvelable pour 5 ans supplémentaires. L'accord comprend des frais de licence nominaux de 1 $ et une structure de redevances de 5 % sur les ventes brutes jusqu'à 1 000 000 $, réduisant à 2,5 % pour les ventes dépassant 1 000 000 $.
L'accord, conclu avec une entreprise contrôlée par l'un des directeurs de Restart Life, inclut une marque de soins de santé générant auparavant des revenus et opérant sur Amazon. Les redevances peuvent être payées en espèces, en actions ordinaires de la société ou dans une combinaison des deux. Les deux parties ont convenu de négocier l'achat des marques licenciées à la fin de la période.
La transaction est exemptée des exigences d'évaluation formelle et des exigences d'approbation des actionnaires minoritaires en vertu de l'instrument multilatéral 61-101 sur la protection des actionnaires minoritaires dans les transactions spéciales.
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) hat sich exklusive Lizenzrechte an vier gesundheitsbezogenen Marken im Rahmen eines 5-Jahres-Vertrags gesichert, der um weitere 5 Jahre verlängert werden kann. Der Vertrag umfasst eine nominelle Lizenzgebühr von $1 und eine Lizenzstruktur von 5% auf den Bruttoverkauf bis zu $1.000.000, die auf 2,5% für Verkäufe über $1.000.000 sinkt.
Der Vertrag, der mit einem Unternehmen geschlossen wurde, das von einem der Direktoren von Restart Life kontrolliert wird, beinhaltet eine zuvor Einnahmen generierende Gesundheitsmarke, die auf Amazon tätig war. Die Lizenzgebühren können in bar, in Stammaktien des Unternehmens oder in einer Kombination aus beidem gezahlt werden. Beide Parteien haben sich darauf geeinigt, am Ende der Laufzeit über den Kauf der lizenzierten Marken zu verhandeln.
Die Transaktion ist von den Anforderungen an eine formelle Bewertung und den Anforderungen an die Genehmigung von Minderheitsaktionären gemäß dem Multilateralen Instrument 61-101 zum Schutz von Minderheitsaktionären bei Sondertransaktionen befreit.
- Minimal initial investment with $1 licensing fee
- Flexible royalty payment options including cash or shares
- Access to previously successful Amazon health-care brand
- Option to purchase trademarks at end of term
- Related party transaction with director-controlled company
- Ongoing royalty obligations of 5% on sales up to $1M
- Purchase price for trademarks not predetermined
- Previous brand ceased operations due to economic conditions
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to announce that it has secured the licensing rights to health-related trademarks, a strategic move that will play a role in the Company's future brand development initiatives. This agreement aligns with Restart Life's efforts to strengthen its market position and expand its product portfolio.
Restart Life has secured an exclusive license to use four trademarks for its products under a 5-year agreement, with a renewal option for another 5 years.
The license agreement, made with a company controlled by one of the Company's directors, includes a
The Company and the licensor agreed to negotiate the purchase of the licensed trade marks at the end of the term. The acquisition price will be negotiated and mutually agreed upon by both parties at the time of the acquisition.
In a further strategic move, the agreement includes a health-care-related brand which was revenue producing through sales of health-related products on Amazon. The brand was originally developed by one of Restart Life's directors, who chose to cease operations due to economic conditions during and post-covid. Restart Life expects to receive valuable business insights to assist in revitalizing and relaunching the brand, leveraging past successes to achieve future growth.
The Company remains committed to expanding its intellectual property through a variety of agreements, acquisitions, and joint ventures to enhance its market presence and drive innovation.
"We are excited to move forward with this strategic licensing agreement, which positions Restart Life to strengthen its brand portfolio and accelerate market growth," said Steve Loutskou, CEO of Restart Life. "By acquiring these trademark licensing rights at a minimal cost, we are well-positioned to expand our product offerings, build brand awareness, and explore new business opportunities in the years to come."
The license agreement has been approved by the independent directors of the Company. The transaction is exempt from the formal valuation requirements pursuant to sections 5.5(a) Fair Market Value not More Than
Restart Life looks forward to leveraging these new licensing rights to drive innovation and introduce new products that will resonate with its growing customer base.
About Restart Life Sciences Corp.
Restart Life Science Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.
Forward-Looking Information
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
The forward-looking statements in this news release include but are not limited to the statements related to the trade marks, the use of the trade marks, the license agreement, Company's position in the market and market growth.
The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various risk factors, including, but not limited to the ability to sell Company's products, appeal of the trademarks and Company's products to consumers, regulatory environment, taxes and tariffs.
The material assumptions used to develop forward-looking information include, but not limited to general business and economic conditions, financial markets conditions, the Company's ability to fund its operations, obtain licensees and/or permits (when required), develop, market and sell its products.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intention to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the board of directors
Chief Executive Officer - Steve Loutskou
Tel: +1 (778) 819-0244
Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244643
FAQ
What are the key terms of Restart Life Sciences (NMLSD) trademark licensing agreement?
How can Restart Life Sciences (NMLSD) pay the royalties under the new licensing agreement?
What is the potential acquisition arrangement for the NMLSD licensed trademarks?
What existing brand is included in Restart Life Sciences' (NMLSD) licensing agreement?
